Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Woong-Yang Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests
Jihun Kim, Woong-Yang Park, Nayoung K. D. Kim, Se Jin Jang, Sung-Min Chun, Chang-Ohk Sung, Jene Choi, Young-Hyeh Ko, Yoon-La Choi, Hyo Sup Shim, Jae-Kyung Won
J Pathol Transl Med. 2017;51(3):191-204.   Published online May 10, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.14
  • 22,947 View
  • 1,056 Download
  • 30 Web of Science
  • 31 Crossref
AbstractAbstract PDF
Next-generation sequencing (NGS) has recently emerged as an essential component of personalized cancer medicine due to its high throughput and low per-base cost. However, no sufficient guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel testing procedures and requirements for clinical implementation of NGS. This consensus standard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS laboratories. The laboratory guidelines part addressed several important issues across multistep NGS cancer panel tests including choice of gene panel and platform, sample handling, nucleic acid management, sample identity tracking, library preparation, sequencing, analysis and reporting. Requirements for clinical NGS tests were summarized in terms of documentation, validation, quality management, and other required written policies. Together with appropriate pathologist training and international laboratory standards, these laboratory standards would help molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In this way, the oncology community would be able to help patients to benefit more from personalized cancer medicine.

Citations

Citations to this article as recorded by  
  • Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors
    Moonsik Kim, Changseon Lee, Juyeon Hong, Juhee Kim, Ji Yun Jeong, Nora Jee-Young Park, Ji-Eun Kim, Ji Young Park
    Cancer Research and Treatment.2023; 55(2): 429.     CrossRef
  • Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists
    Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee
    Journal of Pathology and Translational Medicine.2023; 57(5): 265.     CrossRef
  • Clinical applications of next-generation sequencing in the diagnosis of genetic disorders in Korea: a narrative review
    Jihoon G. Yoon, Man Jin Kim, Yong Jin Kwon, Jong-Hee Chae
    Journal of the Korean Medical Association.2023; 66(10): 613.     CrossRef
  • Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study
    Mustafa Umit Oner, Jianbin Chen, Egor Revkov, Anne James, Seow Ye Heng, Arife Neslihan Kaya, Jacob Josiah Santiago Alvarez, Angela Takano, Xin Min Cheng, Tony Kiat Hon Lim, Daniel Shao Weng Tan, Weiwei Zhai, Anders Jacobsen Skanderup, Wing-Kin Sung, Hwee
    Patterns.2022; 3(2): 100399.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data
    Chad M. Vanderbilt, Anita S. Bowman, Sumit Middha, Kseniya Petrova-Drus, Yi-Wei Tang, Xin Chen, Youxiang Wang, Jason Chang, Natasha Rekhtman, Klaus J. Busam, Sounak Gupta, Meera Hameed, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Snjezana Dogan, Ahm
    The Journal of Molecular Diagnostics.2022; 24(5): 515.     CrossRef
  • Performance Evaluation of Three DNA Sample Tracking Tools in a Whole Exome Sequencing Workflow
    Gertjan Wils, Céline Helsmoortel, Pieter-Jan Volders, Inge Vereecke, Mauro Milazzo, Jo Vandesompele, Frauke Coppieters, Kim De Leeneer, Steve Lefever
    Molecular Diagnosis & Therapy.2022; 26(4): 411.     CrossRef
  • Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development
    Timothé Ménard, Alaina Barros, Christopher Ganter
    Therapeutic Innovation & Regulatory Science.2021; 55(5): 1066.     CrossRef
  • Fast Healthcare Interoperability Resources (FHIR)–Based Quality Information Exchange for Clinical Next-Generation Sequencing Genomic Testing: Implementation Study
    Donghyeong Seong, Sungwon Jung, Sungchul Bae, Jongsuk Chung, Dae-Soon Son, Byoung-Kee Yi
    Journal of Medical Internet Research.2021; 23(4): e26261.     CrossRef
  • Status of Next-Generation Sequencing-Based Genetic Diagnosis in Hematologic Malignancies in Korea (2017-2018)
    JinJu Kim, Ja Young Lee, Jungwon Huh, Myung-Hyun Nam, Myungshin Kim, Young-Uk Cho, Sun-Young Kong, Seung-Tae Lee, In-Suk Kim
    Laboratory Medicine Online.2021; 11(1): 25.     CrossRef
  • MSI-Testung
    Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars-Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel, Doris Mayr, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus, Peter Schirmacher, Mark
    Der Pathologe.2021; 42(4): 414.     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • MSI testing
    Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars-Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel, Doris Mayr, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus, Peter Schirmacher, Mark
    Der Pathologe.2021; 42(S1): 110.     CrossRef
  • 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer
    Huisong Lee, Hyeon Kook Lee, Seog Ki Min, Won Hee Lee
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
    Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
    Thyroid.2020; 30(11): 1589.     CrossRef
  • Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape
    Anurag Mehta, Smreti Vasudevan, Sanjeev Kumar Sharma, Manoj Panigrahi, Moushumi Suryavanshi, Mumtaz Saifi, Ullas Batra
    Applied Cancer Research.2020;[Epub]     CrossRef
  • Application Areas of Traditional Molecular Genetic Methods and NGS in relation to Hereditary Urological Cancer Diagnosis
    Dmitry S. Mikhaylenko, Alexander S. Tanas, Dmitry V. Zaletaev, Marina V. Nemtsova
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Assembling and Validating Bioinformatic Pipelines for Next-Generation Sequencing Clinical Assays
    Jeffrey A SoRelle, Megan Wachsmann, Brandi L. Cantarel
    Archives of Pathology & Laboratory Medicine.2020; 144(9): 1118.     CrossRef
  • Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples
    Erica K. Barnell, Peter Ronning, Katie M. Campbell, Kilannin Krysiak, Benjamin J. Ainscough, Lana M. Sheta, Shahil P. Pema, Alina D. Schmidt, Megan Richters, Kelsy C. Cotto, Arpad M. Danos, Cody Ramirez, Zachary L. Skidmore, Nicholas C. Spies, Jasreet Hun
    Genetics in Medicine.2019; 21(4): 972.     CrossRef
  • A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously
    Zoltán A. Mezei, Dávid Tornai, Róza Földesi, László Madar, Andrea Sümegi, Mária Papp, Péter Antal-Szalmás
    Journal of Biotechnology.2019; 303: 25.     CrossRef
  • Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges
    Hippman, Nislow
    Journal of Personalized Medicine.2019; 9(3): 40.     CrossRef
  • Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
    Dohee Kwon, Binnari Kim, Hyeong Chan Shin, Eun Ji Kim, Sang Yun Ha, Kee-Taek Jang, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Joon Oh Park, Kyoung-Mee Kim
    Translational Oncology.2019; 12(11): 1488.     CrossRef
  • Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA
    Mancini, Simi, Salvianti, Castiglione, Sonnati, Pinzani
    Diagnostics.2019; 9(3): 117.     CrossRef
  • Benchmark Database for Process Optimization and Quality Control of Clinical Cancer Panel Sequencing
    Donghyeong Seong, Jongsuk Chung, Ki-Wook Lee, Sook-Young Kim, Byung-Suk Kim, Jung-Keun Song, Sungwon Jung, Taeseob Lee, Donghyun Park, Byoung-Kee Yi, Woong-Yang Park, Dae-Soon Son
    Biotechnology and Bioprocess Engineering.2019; 24(5): 793.     CrossRef
  • Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients
    Simon Heeke, Véronique Hofman, Elodie Long-Mira, Virginie Lespinet, Salomé Lalvée, Olivier Bordone, Camille Ribeyre, Virginie Tanga, Jonathan Benzaquen, Sylvie Leroy, Charlotte Cohen, Jérôme Mouroux, Charles Marquette, Marius Ilié, Paul Hofman
    Cancers.2018; 10(4): 88.     CrossRef
  • Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay
    Ahwon Lee, Sung-Hak Lee, Chan Kwon Jung, Gyungsin Park, Kyo Young Lee, Hyun Joo Choi, Ki Ouk Min, Tae Jung Kim, Eun Jung Lee, Youn Soo Lee
    Pathology - Research and Practice.2018; 214(5): 713.     CrossRef
  • Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor
    Jeong-Mo Bae, Jae-Kyung Won, Sung-Hye Park
    Journal of Korean Neurosurgical Society.2018; 61(3): 376.     CrossRef
  • The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics
    Caterina Fumagalli, Davide Vacirca, Alessandra Rappa, Antonio Passaro, Juliana Guarize, Paola Rafaniello Raviele, Filippo de Marinis, Lorenzo Spaggiari, Chiara Casadio, Giuseppe Viale, Massimo Barberis, Elena Guerini-Rocco
    Journal of Clinical Pathology.2018; 71(9): 767.     CrossRef
  • Clinical laboratory utilization management and improved healthcare performance
    Christopher Naugler, Deirdre L. Church
    Critical Reviews in Clinical Laboratory Sciences.2018; 55(8): 535.     CrossRef
  • Development of HLA-A, -B and -DR Typing Method Using Next-Generation Sequencing
    Dong Hee Seo, Jeong Min Lee, Mi Ok Park, Hyun Ju Lee, Seo Yoon Moon, Mijin Oh, So Young Kim, Sang-Heon Lee, Ki-Eun Hyeong, Hae-Jin Hu, Dae-Yeon Cho
    The Korean Journal of Blood Transfusion.2018; 29(3): 310.     CrossRef
  • Value-based genomics
    Jun Gong, Kathy Pan, Marwan Fakih, Sumanta Pal, Ravi Salgia
    Oncotarget.2018; 9(21): 15792.     CrossRef
Original Article
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Soomin Ahn, Soo Hyun Hwang, Joungho Han, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Woong-Yang Park
J Pathol Transl Med. 2016;50(4):258-263.   Published online May 10, 2016
DOI: https://doi.org/10.4132/jptm.2016.04.19
  • 10,646 View
  • 235 Download
  • 45 Web of Science
  • 40 Crossref
AbstractAbstract PDF
Background
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first line treatment for a subset of EGFR-mutated non-small cell lung cancer (NSCLC) patients. Although transformation to small cell lung cancer (SCLC) is one of the known mechanisms of resistance to EGFR TKIs, it is not certain whether transformation to SCLC is exclusively found as a mechanism of TKI resistance in EGFR-mutant tumors.
Methods
We identified six patients with primary lung adenocarcinoma that showed transformation to SCLC on second biopsy (n = 401) during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were compared between initial and second biopsy samples.
Results
Six patients showed transformation from adenocarcinoma to SCLC, of which four were pure SCLCs and two were combined adenocarcinoma and SCLCs. Clinically, four cases were EGFR-mutant tumors from non-smoking females who underwent TKI treatment, and the EGFR mutation was retained in the transformed SCLC tumors. The remaining two adenocarcinomas were EGFR wild-type, and one of these patients received EGFR TKI treatment.
Conclusions
NSCLC can acquire a neuroendocrine phenotype with or without EGFR TKI treatment.

Citations

Citations to this article as recorded by  
  • Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
    Xi Ding, Min-xing Shi, Di Liu, Jing-xue Cao, Kai-xuan Zhang, Run-dong Zhang, Li-ping Zhang, Kai-xing Ai, Bo Su, Jie Zhang
    Cell Communication and Signaling.2024;[Epub]     CrossRef
  • The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
    Alessandra Ferro, Gian Marco Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno
    Critical Reviews in Oncology/Hematology.2024; 196: 104295.     CrossRef
  • Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
    Kresimir Tomic, Kristina Krpina, Lara Baticic, Miroslav Samarzija, Semir Vranic
    Journal of Drug Targeting.2024; : 1.     CrossRef
  • Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
    Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania
    Current Oncology.2023; 30(3): 3494.     CrossRef
  • Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
    Giuseppe Giaccone, Yongfeng He
    Seminars in Cancer Biology.2023; 94: 1.     CrossRef
  • Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
    Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, Parthasarathy Seshacharyulu
    Expert Opinion on Therapeutic Targets.2023; 27(4-5): 305.     CrossRef
  • Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
    Jinhe Xu, Lihuan Xu, Baoshan Wang, Wencui Kong, Ying Chen, Zongyang Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Small cell lung cancer transformation: From pathogenesis to treatment
    Xiaomeng Yin, Yueyi Li, Hang Wang, Tingting Jia, Enli Wang, Yuling Luo, Yuhao Wei, Zeyi Qin, Xuelei Ma
    Seminars in Cancer Biology.2022; 86: 595.     CrossRef
  • Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
    Journal of Clinical Medicine.2022; 11(5): 1429.     CrossRef
  • Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
    Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman
    International Journal of Molecular Sciences.2022; 23(8): 4164.     CrossRef
  • Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
    Ugo Testa, Elvira Pelosi, Germana Castelli
    Onco.2022; 2(3): 186.     CrossRef
  • Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon
    Xiao Chu, Yuyin Xu, Ye Li, Yue Zhou, Li Chu, Xi Yang, Jianjiao Ni, Yida Li, Tiantian Guo, Zhiqin Zheng, Qiang Zheng, Qianlan Yao, Yuan Li, Xiaoyan Zhou, Zhengfei Zhu
    Lung Cancer.2022; 169: 22.     CrossRef
  • Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
    Ling Chen, Yangqingqing Zhou, Chaosheng Gan, XiaoLi Wang, Yihui Liu, Chunhui Dong, Ruiyuan He, Jin Yang
    Cancer Investigation.2022; 40(7): 590.     CrossRef
  • Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
    Hao Liu, Li-Hong Chen, Zhi-Hui Zhang, Ning Wang, Si-Hui Zhuang, Hao Chen, Jin Du, Li-Juan Pang, Yan Qi
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Ca
    npj Precision Oncology.2021;[Epub]     CrossRef
  • Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
    Cai-Bao Jin, Ling Yang
    World Journal of Clinical Cases.2021; 9(18): 4617.     CrossRef
  • Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
    Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu, Tomoko Sakyo, Masanori Abe, Honami Yonezawa, Fumito Ishibashi, Masaaki Matsuura, Akihiro Tomida, Hiroyuki Sei
    Cancer Science.2021; 112(5): 1963.     CrossRef
  • Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
    Qian Shen, Jingjing Qu, Lingyan Sheng, Qiqi Gao, Jianying Zhou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
    Kyoungmin Lee, Deokhoon Kim, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim
    European Journal of Cancer.2021; 148: 202.     CrossRef
  • Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
    Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing
    Thoracic Cancer.2021; 12(19): 2585.     CrossRef
  • EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs
    Chih-An Lin, Sung-Liang Yu, Hsuan-Yu Chen, Huei-Wen Chen, Shr-Uen Lin, Chia-Ching Chang, Chong-Jen Yu, Pan-Chyr Yang, Chao-Chi Ho
    Journal of Thoracic Oncology.2019; 14(3): 513.     CrossRef
  • The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer
    Haiyan Yang, Li Liu, Chunhua Zhou, Yi Xiong, Yijuan Hu, Nong Yang, Jingjing Qu
    Medicine.2019; 98(12): e14893.     CrossRef
  • Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents
    Olayinka O. Ajani, Martins T. Nlebemuo, Joseph A. Adekoya, Kehinde O. Ogunniran, Tolutope O. Siyanbola, Christiana O. Ajanaku
    Acta Pharmaceutica.2019; 69(2): 177.     CrossRef
  • Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
    Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu
    Critical Reviews in Oncology/Hematology.2018; 123: 149.     CrossRef
  • Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review
    Yangyang Liu
    Cancer Biology & Therapy.2018; 19(6): 445.     CrossRef
  • Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
    Jongmin Sim, Hyunjin Kim, Jiyeon Hyeon, Yoon-La Choi, Joungho Han
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
    Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne
    JAMA Oncology.2018; 4(11): 1527.     CrossRef
  • Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
    Mong-Wei Lin, Kang-Yi Su, Te-Jen Su, Chia-Ching Chang, Jing-Wei Lin, Yi-Hsuan Lee, Sung-Liang Yu, Jin-Shing Chen, Min-Shu Hsieh
    Lung Cancer.2018; 125: 282.     CrossRef
  • Transformation to small‑cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma
    Hongyang Lu, Bo Chen, Jing Qin, Fajun Xie, Na Han, Zhiyu Huang
    Oncology Letters.2018;[Epub]     CrossRef
  • Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature
    Monalisa Hui, ShantveerG Uppin, BalaJoseph Stalin, G Sadashivudu
    Lung India.2018; 35(2): 160.     CrossRef
  • A rare case of squamous cell carcinoma lung with multiple locoregional recurrences and histological transformation
    Ram Niwas, Shibdas Chakrabarti, Viswesvaran Balasubramanian, ManasKamal Sen, JagdishChander Suri
    Lung India.2018; 35(6): 511.     CrossRef
  • Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
    Takuma Imakita, Kohei Fujita, Osamu Kanai, Tsuyoshi Terashima, Tadashi Mio
    Respiratory Medicine Case Reports.2017; 21: 52.     CrossRef
  • Pulmonary neuroendocrine tumor in a female wolf (Canis lupus lupus)
    Ayako SHIRAKI, Toshinori YOSHIDA, Masahi KAWASHIMA, Hirotada MURAYAMA, Rei NAGAHARA, Nanao ITO, Makoto SHIBUTANI
    Journal of Veterinary Medical Science.2017; 79(3): 588.     CrossRef
  • Secondary biopsy of non‐oncogenic‐driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases
    Maria C. Mengoli, Giulia Orsi, Filippo Lococo, Giulia Grizzi, Fausto Barbieri, Federica Bertolini, Giulio Rossi, Silvia Novello
    Thoracic Cancer.2017; 8(4): 359.     CrossRef
  • Small-cell lung cancer in never smokers: The clinicopathological features including the prognosis
    Masahiro Yamasaki, Naomi Saito, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Akio Sakatani, Megumu Fujihara, Nobuyuki Ohashi, Ken-ichi Arita
    Cancer Treatment and Research Communications.2017; 12: 1.     CrossRef
  • Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
    June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se-Hoon Lee, Keunchil Park, Ja-Lok Ku, Yoon Kyung Jeon, Doo Hyun
    Journal of Clinical Oncology.2017; 35(26): 3065.     CrossRef
  • Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
    Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis
    Asia-Pacific Journal of Clinical Oncology.2017; 13(4): 296.     CrossRef
  • Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
    Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han
    Journal of Pathology and Translational Medicine.2017; 51(4): 441.     CrossRef
  • Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin Khan, Hafiz Khan, Susan Smith, Yanis Boumber
    Cancer Biology & Therapy.2017; 18(12): 940.     CrossRef
  • The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance
    Shanling Mu, Hong Ma, Jun Shi, Dezhi Zhen
    Oncology Letters.2017;[Epub]     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine